MetaCap

Phio Pharmaceuticals (PHIO) vs Quantum Biopharma (QNTM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Phio Pharmaceuticals (PHIO) has outperformed Quantum Biopharma (QNTM) over the past year, losing 41.4% versus a loss of 77.6%. Over five years, QNTM leads with a -98.5% price change compared with -99.6% for PHIO. Quantum Biopharma is the larger company by market cap ($8.3 million vs $7.8 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PHIO-41.43%QNTM-77.60%
+107%+10%-86%
Nov 21, 20251 yearNov 20, 2026
PHIO-99.56%QNTM-98.66%
+80%-14%-108%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PHIO versus QNTM key metrics
MetricPHIOQNTM
Share price$0.656$1.29
Market cap$7.84M$8.29M
1-day change-8.25%-9.15%
YTD return-37.52%-82.33%
1-year return-41.43%-77.60%
5-year return-99.56%-98.51%
EPS (TTM)$-1.21$-3.42
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-8.70M—
52-week high$1.88$12.42
52-week low$0.6395$1.26
Distance from 52-week high-65.11%-89.61%
Analyst consensusnonenone
Avg. price target upside+2034.15%+851.16%
Average volume106.09K148.83K
Shares outstanding11.95M6.43M
Employees6—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PHIO has outperformed QNTM by 36.2 percentage points over the past year.

About Phio Pharmaceuticals

PHIO stock →

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Quantum Biopharma

QNTM stock →

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments.

Health Care · Biotechnology: Pharmaceutical Preparations

PHIO vs QNTM FAQ

Which is bigger, Phio Pharmaceuticals or Quantum Biopharma?

Quantum Biopharma (QNTM) is larger, with a market capitalization of $8.29M compared with $7.84M for Phio Pharmaceuticals (PHIO).

Which stock has performed better over the past year, PHIO or QNTM?

PHIO returned -41.43% over the past 12 months, compared with -77.60% for QNTM (price return, excluding dividends). Past performance does not predict future results.

Are Phio Pharmaceuticals and Quantum Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons